Project Details
Projekt Print View

Mucosal-associated invariant T cells in Hepatocellular Carcinoma

Applicant Dr. Simon Wabitsch
Subject Area Hematology, Oncology
Term from 2019 to 2022
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 430914934
 
Final Report Year 2022

Final Report Abstract

The initial research plan focused on exploring the immune landscape of HCC and MAIT cells in HCC. Due to the COVID-19 pandemic we changed the focus of the research plan on the influences of ICI therapy. Starting with a COVID-19 related project, two further projects were established with the overall question which patient or medication dependent circumstances influence the response to ICI therapy. We used well-annoted murine tumor modes as well as comprehensive immunophenotyping via multiplex immunostaining and sequencing to refine our understanding of T cell response to ICI therapy. We were also able to show CD8+ T cell mobility at the border and core of HCC in vivo for the first time. Additionally, using sorted hepatic CD8+ T cells for mobility experiments ex vivo allowed us to investigate if changes of CD8+ T cells is dependent on the hepatic and intra-tumoral environment or an CD8+ T cell intrinsic effect. With these results we were able to establish a combination therapy for iCC using trametinib+anti-PD-1 as well as metformin+ICI therapy for HCC in NASH. These findings have implications for clinical practice: as a potential treatment strategy for iCC as well as a new combination therapy for NASH patients with HCC.

Publications

 
 

Additional Information

Textvergrößerung und Kontrastanpassung